Gattex grabs early US FDA nod, but NPS investors not impressed
This article was originally published in Scrip
Executive Summary
Whether it was the holiday spirit or just wanting to clear their desks of applications, US regulators on 21 December granted an earlier-than-expected approval to NPS Pharmaceuticals to market Gattex (teduglutide) as a subcutaneous treatment for adults with short bowel syndrome (SBS) dependent on parenteral support.